Publications Policy Sample Clauses

Publications Policy. Both Parties shall have the right to use and publish any information derived from the work or project under this Agreement provided that written consent is obtained from the other Party. In the event that any Parties, wishes to publish, disclose and/ or present (in any form of disclosure) the data and/ or outcome arising from this Agreement, the Party shall submit a draft of each such publication or presentation to the other Party and give the right to the other Party to have certain parts of the said publication. In any such publications, the contribution of both Parties shall be acknowledged.
Sample 1Sample 2Sample 3See All (7)
AutoNDA by SimpleDocs
Publications Policy. The release of pre-publication data from large resource-generating scientific projects was the subject of a meeting held in January 2003, the "Fort Lauderdale meeting", sponsored by the Wellcome Trust. The report from that meeting can be viewed at xxxx://xxx.xxxxxxxx.xx.xx/assets/wtd003207.pdf. The recommendations of the Fort Lauderdale meeting address the roles and responsibilities of data producers, data users, and funders of 'community resource projects', with the aim of establishing and maintaining an appropriate balance between the interests of data users in rapid access to data and the needs of data producers to receive recognition for their work. The WTCCC has agreed to follow these data-release principles and as such, these data are being released as a 'community resource project' as defined in the report of the Fort Lauderdale meeting. The WTCCC, as a data producer, reserves the right to publish the initial global analyses of the data. In so doing, it will also ensure that the data generated are fully described.
Sample 1Sample 2Sample 3
Publications Policy. The primary purpose of the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) is to identify all inherited and tumor-acquired (somatic) genome sequence and structural variants influencing the development and behaviour of childhood tumors. Additional objectives include, but are not limited to, the acquisition and analysis of additional genomic data, including epigenetic and gene expression data, data integration, and the development and validation of informatic and analytical solutions appropriate to the scale and nature of the project, as well as use of the data generated to answer important methodological and biological questions studies of tumor biology in general, and as specifically related to childhood malignancies. The PCGP anticipates that data generated from the project will be used by other researchers (scientists who are employed by, or a student enrolled at or legitimately affiliated with, an academic, non-profit, or government institution, or a commercial company) to develop new analytical methods, validate results, and identify additional genetic variations and alterations in the data.
Sample 1Sample 2
Publications Policy. If Supplier provides assistance in producing publications and presentations, Supplier agrees to adhere to the requirements set forth in AstraZeneca’s Global Publications Policy, which can be found at: xxxxx://xxx.xxxxxxxxxxx.xxx/content/dam/az/our-company/Sustainability/Publications-Policy.pdf, along with any applicable standards provided to Supplier by the AstraZeneca project manager. Such requirements include, but are not limited to:
Sample 1Sample 2
Publications Policy. Authors who use data from the H3Africa consortium must acknowledge H3Africa using the following wording "This study makes use of data generated by H3Africa. A full list of the investigators who contributed to the generation of the data is available from xxxxx://x0xxxxxx.xxx. The funding for this project comes through the Human Heredity and Health in Africa (H3Africa) Initiative, which is funded by the National Institutes of Health and the Wellcome Trust through AAS. Authors must also cite the relevant primary H3Africa publication (details of which can be found on the H3Africa website) and the information about which H3Africa datasets were used.
Sample 1
Publications Policy. PUBLICATIONS AND INDUSTRIAL AND/OR INTELLECTUAL PROPERTY RIGHTS
Sample 1
Publications Policy. Any publications based on the results of the trial shall conform to the conditions in the "Advance Understanding" in the contract with the University of Maryland, Contract
Sample 1
AutoNDA by SimpleDocs
Publications Policy. The release of pre-publication data from large resource-generating scientific projects was the subject of a meeting held in January 2003, the "Fort Lauderdale meeting", sponsored by the Wellcome Trust. The report from that meeting can be viewed at xxxx://xxx.xxxxxxxx.xx.xx/assets/wtd003207.pdf. The recommendations of the Fort Lauderdale meeting address the roles and responsibilities of data producers, data users, and funders of 'community resource projects', with the aim of establishing and maintaining an appropriate balance between the interests of data users in rapid access to data and the needs of data producers to receive recognition for their work. The Telethon Kids Institute and the Menzies School of Health Research have agreed to follow these data-release principles and as such, these data are being released as a 'community resource project' as defined in the report of the Fort Lauderdale meeting. The Telethon Kids Institute and the Menzies School of Health Research, as data producers, reserve the right to publish the initial global analyses of the data. In so doing, it will also ensure that the data generated are fully described.
Sample 1
Publications Policy. The primary purpose of the Wellcome Trust Case-Control Consortium (WTCCC) is to accelerate efforts to identify genome sequence variants influencing major causes of human morbidity and mortality, through implementation and analysis of large-scale genome-wide association studies. Additional objectives include the development and validation of informatics and analytical solutions appropriate to the scale and nature of the project, as well as use of the data generated to answer important methodological and biological questions relevant to association studies in general, and in the UK in particular. The Consortium anticipates that data generated from the project will be used by others, such as required for developing new analytical methods, in understanding patterns of polymorphism and in guiding selection of markers to map genes involved in specific diseases. A more detailed list of the WTCCC aims are provided on the WTCCC website – xxx.xxxxx.xxx.xx
Sample 1

Related to Publications Policy

  • Publications All published material and written reports submitted under the Contract must be originally developed material unless otherwise specifically provided in the Contract. When material not originally developed is included in a report in any form, the source shall be identified.

  • Scientific Publications During the Research Program Term, neither Party shall first publish or first present in a public forum the scientific or technical results of any activity performed pursuant to this Agreement without the opportunity for prior review and comment by the other Party. Each Party agrees to provide the other Party with the opportunity to review any proposed abstract, manuscript or scientific presentation (including any verbal presentation) that relates to its activities performed pursuant to this Agreement during the Research Program Term, at least [**] days prior to its intended submission for publication and agrees, upon request, not to submit any such abstract or manuscript for publication until the other Party is given a reasonable period of time up to [**] to secure patent protection for any material in such publication that it believes to be patentable. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications first with respect to activities performed or results obtained pursuant to this Agreement during the Research Program Term, or not to publish at all if necessary to preserve trade secrets. The Parties agree to review and decide whether to delay publication of such information to permit filing of patent applications. Neither Party shall have the right to publish or present any Confidential Information of the other Party, except as provided in Section 9.2. After the Research Program Term, each Party and its Affiliates may publish or present results, data or scientific findings of any of their activities without the prior review of the other Party, provided that such publication or presentation does not disclose any of the other Party’s Confidential Information. Nothing contained in this Section 9.3 shall prohibit the inclusion of information necessary for a patent application; provided that the non-filing Party is given a reasonable opportunity to review the information to be included prior to submission of such patent application in accordance with Section 8.2. Nothing contained in this Section 9.3 shall prohibit either Party from disclosing the results, data or scientific findings of any activity performed by the other Party or its Affiliates pursuant to this Agreement without prior review and prior written consent of the other Party, where required, as reasonably determined by the disclosing Party’s legal counsel, by applicable law; provided that if a Party is required by law to make any such disclosure, to the extent it may legally do so, it will give reasonable advance notice to the other Party of such disclosure and will use its reasonable efforts to secure confidential treatment of such information prior to its disclosure (whether through protective orders or otherwise).

  • Policy Statement The RSU Award grant the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability. The Company, with registered offices at Xxx Xxxxxx Xxxxxxxxx, #00-00, Xxxxxxxxx 000000, is solely responsible for the administration of the Plan, and participation in the Plan and the grant of the RSU Award do not, in any way, establish an employment relationship between the Participant and the Company since he or she is participating in the Plan on a wholly commercial basis and the sole employer is Availmed Servicios S.A. de C.V., Grupo Flextronics S.A. de C.V., Flextronics Servicios Guadalajara S.A. de C.V., Flextronics Servicios Mexico S. de X.X. de C.V. and Flextronics Aguascalientes Servicios S.A. de C.V., nor does it establish any rights between the Participant and the Employer. Plan Document Acknowledgment. By accepting the RSU Award, the Participant acknowledges that he or she has received copies of the Plan, has reviewed the Plan and the Agreement in their entirety, and fully understands and accepts all provisions of the Plan and the Agreement. In addition, the Participant further acknowledges that he or she has read and specifically and expressly approves the terms and conditions in the Nature of Grant section of the Agreement, in which the following is clearly described and established: (i) participation in the Plan does not constitute an acquired right; (ii) the Plan and participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) participation in the Plan is voluntary; and (iv) the Company and any Parent, Subsidiary or Affiliates are not responsible for any decrease in the value of the Shares acquired upon vesting of the RSU Award. Finally, the Participant hereby declares that he or she does not reserve any action or right to bring any claim against the Company for any compensation or damages as a result of his or her participation in the Plan and therefore grants a full and broad release to the Employer, the Company and any Parent, Subsidiary or Affiliates with respect to any claim that may arise under the Plan.

  • Publications and Presentations For purposes of this Agreement, “Scientific Publication” means any scientific publication or medical communication regarding Study results in any form that is intended for disclosure to third parties, including, without limitation, manuscripts, abstracts, posters, slides or other materials used for presentations. 10. Publikace a prezentace. „Vědecká publikace“ znamená pro účely této Smlouvy každou vědeckou publikaci nebo lékařské sdělení týkající se výsledků Studie, v libovolné formě určené ke sdělení třetím stranám, zejména rukopisy, abstrakty, postery, snímky nebo jiné materiály používané pro prezentace.

  • Disclosures Vendor and TIPS affirms that he/she or any authorized employees or agents has not given, offered to give, nor intends to give at any time hereafter any economic opportunity, future employment, gift, loan, gratuity, special discount, trip, favor or service to a public servant in connection with this Agreement. • Vendor shall attach, in writing, a complete description of any and all relationships that might be considered a conflict of interest in doing business with the TIPS program. • The Vendor affirms that, to the best of his/her knowledge, the offer has been arrived at independently, and is submitted without collusion with anyone to obtain information or gain any favoritism that would in any way limit competition or give an unfair advantage over other vendors in the award of this Agreement.

  • Non-Publication The parties mutually agree not to disclose publicly the terms of this Agreement except to the extent that disclosure is mandated by applicable law or regulation or to their respective advisors (e.g., attorneys, accountants).

  • Rules, Regulations and Policies Employee shall abide by and comply with all of the rules, regulations, and policies of Employer, including without limitation Employer's policy of strict adherence to, and compliance with, any and all requirements of the banking, securities, and antitrust laws and regulations.

  • Confidentiality Publication (a) Background Intellectual Property and Project Intellectual Property of a party, as well as other proprietary or confidential information of a party, disclosed by that party to the other in connection with this STTR project shall be received and held in confidence by the receiving party and, except with the consent of the disclosing party or as permitted under this Agreement, neither used by the receiving party nor disclosed by the receiving party to others, provided that the receiving party has notice that such information is regarded by the disclosing party as proprietary or confidential. However, these confidentiality obligations shall not apply to use or disclosure by the receiving party after such information is or becomes known to the public without breach of this provision or is or becomes known to the receiving party from a source reasonably believed to be independent of the disclosing party or is developed by or for the receiving party independently of its disclosure by the disclosing party.

  • Investment Policies The Borrower is in compliance in all material respects with the Investment Policies.

  • Predatory Lending Regulations No Mortgage Loan is a High Cost Loan or Covered Loan, as applicable, and no Mortgage Loan originated on or after October 1, 2002 through March 6, 2003 is governed by the Georgia Fair Lending Act. No Mortgage Loan is covered by the Home Ownership and Equity Protection Act of 1994 and no Mortgage Loan is in violation of any comparable state or local law;

Time is Money Join Law Insider Premium to draft better contracts faster.